Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Low-Cost, Easy-to-Use Lab-on-Paper SARS-CoV-2 Diagnostic Test Provides Accurate Results within an Hour

By LabMedica International staff writers
Posted on 21 Jun 2021
Researchers have invented an easy-to-use, affordable lab-on-paper diagnostic technology for SARS-CoV-2, the virus that causes COVID-19 infection, that provides accurate results within an hour.

The device developed by researchers at University of Connecticut (Mansfield, CT, USA) uses a specialized kind of paper material to detect for two SARS-CoV-2 genes - the spike (S) and nucleoprotein (N) genes. More...
The clinical samples validated these genes as good candidates for diagnostic tests because they are highly conserved. This means they are so essential to the virus they are likely found in all variants. By testing two genes rather than one, the test is more accurate.

This point-of-care test can be performed by any health care professional, making it ideal for settings like community health centers. The simple, low-cost device provides a reliable result within an hour. Patients provide a sample from a nasal swap. Then the practitioner uses a commercially available kit to purify the nucleic acid in the sample. This removes any impurities that could interfere with the accuracy of the test. After about 15 minutes, the sample can be transferred to a device that uses CRISPR technology to detect the SARS-CoV-2 genes. CRISPR is a gene-editing technology that can alter an organism’s genome by targeting and cutting specific DNA or RNA segments.

As a diagnostic tool, CRISPR locates the genes of interest, in this case the S and N genes, and cut them. This cut produces an observable signal, which on the device is fluorescence filling in on the paper to indicate a positive result. In addition to the two SARS-CoV-2 genes, the device also tests for a “housekeeping” gene known as the RNase P (RP) gene. The presence of this gene lets the practitioner know they got a high-quality sample that will generate a reliable result. The device is on a cellulose-based paper membrane which is hydrophilic, meaning it can transport the liquid solution that contains the nucleic acid. This is a great advantage to practitioners as the test runs automatically after they load the sample. The paper is also formulated so that it does not interfere with the biochemical reactions that need to happen to select for the genes of interest. If there is interference, the test could produce a false signal. This technology can be applied for diagnosing other pathogens such as HIV, influenza viruses or high-risk HPV by modifying which genes it selects for.

“We took advantage of the high sensitivity and specificity of CRISPR technology,” said Changchun Liu, associate professor in the Department of Biomedical Engineering, who invented the diagnostic technology. “We want to continue to explore this technology and expand it for the detection of other pathogens.”

Related Links:
University of Connecticut


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Test
Epithod616 COVID-19 Ag
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.